Kobayashi Pharmaceutical is considering taking its shares private. The company has received tender offer acquisition proposals from NSSK and CVC Capital Partners, while the founding family is also considering making a partial investment.
Kobayashi Pharmaceutical is reportedly considering taking its shares private. The proposed transaction is said to involve an acquisition through a tender offer. Attention is focused on future developments as the company considers changing its policy.
The acquisition proposals have been made by the Nippon Sangyo Suishin Kiko Group (NSSK) and European investment fund CVC Capital Partners. The market is awaiting further disclosure on whether a tender offer will be conducted and on its terms.
The health-related harm issue involving supplements containing red yeast rice ingredients, which came to light in 2024, has been cited as the backdrop to the company’s restructuring. There is speculation that a restructuring plan under a fund’s ownership is being considered. The founding family is also reportedly considering making a partial investment.